Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15776MR)

This product GTTS-WQ15776MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15776MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11247MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ8195MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ5723MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10397MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15463MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ14928MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ12385MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW